aminolevulinic acid has been researched along with Astrocytoma, Grade IV in 166 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "OBJECT There is evidence that 5-aminolevulinic acid (ALA) facilitates greater extent of resection and improves 6-month progression-free survival in patients with high-grade gliomas." | 9.22 | A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. ( Berger, MS; Chang, S; Hervey-Jumper, SL; Lau, D; McDermott, MW; Molinaro, AM; Phillips, JJ, 2016) |
| " This study is aimed to investigate the clinical availability of 5-aminolevulinic acid (5-ALA)-based PDD and PDT in glioblastoma (GBM) patient-derived tumorspheres (TSs) and mouse orthotopic xenograft model." | 8.31 | C5α secreted by tumor mesenchymal stem-like cells mediates resistance to 5-aminolevulinic acid-based photodynamic therapy against glioblastoma tumorspheres. ( Chang, JH; Huh, YM; Ji, YB; Kang, SG; Kim, EH; Lee, SJ; Moon, JH; Oh, SJ; Park, J; Shim, JK; Suh, JS, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 8.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "This study investigated the degree of tumor cell infiltration in the tumor cavity and ventricle wall based on fluorescent signals of 5-aminolevulinic acid (5-ALA) after removal of the magnetic resonance (MR)-enhancing area and analyzed its prognostic significance in glioblastoma." | 8.02 | Relationship between tumor cell infiltration and 5-aminolevulinic acid fluorescence signals after resection of MR-enhancing lesions and its prognostic significance in glioblastoma. ( Jang, W-; Jung, S; Jung, T-; Kim, I-; Kim, J-; Kim, S-; Lee, K-; Moon, K-, 2021) |
| "5-Aminolevulinic acid (5-ALA) is a naturally occurring non-proteinogenic amino acid, which contributes to the diagnosis and therapeutic approaches of various cancers, including glioblastoma (GBM)." | 8.02 | Antitumor Effects of 5-Aminolevulinic Acid on Human Malignant Glioblastoma Cells. ( Abbasinezhad-Moud, F; Etezad Razavi, M; Gorji, A; Jalili-Nik, M; Khaleghi Ghadiri, M; Maghrouni, A; Sahab-Negah, S; Stummer, W, 2021) |
| "Fluorescence-guided resection of glioblastomas (GBM) using 5-aminolevulinic acid (5-ALA) improves intraoperative tumor visualization and is thus widely used nowadays." | 7.96 | High Interobserver Agreement in the Subjective Classification of 5-Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas. ( Benner, D; Berger, MS; Borkovec, M; Hervey-Jumper, S; Hosmann, A; Kiesel, B; Knosp, E; Mischkulnig, M; Roessler, K; Wadiura, LI; Widhalm, G, 2020) |
| "The usefulness of 5-aminolevulinic acid (5-ALA)-mediated fluorescence-guided surgery (FGS) in meningiomas is intensely discussed." | 7.96 | Real-time in vivo kinetics of protoporphyrin IX after administration of 5-aminolevulinic acid in meningiomas and comparative analyses with glioblastomas. ( Brokinkel, B; Bunk, EC; Hess, K; Holling, M; Kaneko, S; Paulus, W; Senner, V; Stummer, W; Suero Molina, E; Warneke, N, 2020) |
| "Although having shown promising clinical outcomes, the effectiveness of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) for squamous cell carcinoma (SCC) and glioblastoma remains to be improved." | 7.91 | Methadone enhances the effectiveness of 5-aminolevulinic acid-based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro. ( Buchner, A; Gederaas, OA; Pohla, H; Pongratz, T; Rühm, A; Shi, L; Sroka, R; Stepp, H; Wang, X; Zhang, L; Zimmermann, W, 2019) |
| "5-Aminolevulinic acid (5-ALA) has become an important assistant in glioblastoma (GB) surgery." | 7.91 | Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma. ( Bestard Escalas, J; Brell Doval, M; Delgado Sánchez, O; Garfias Arjona, S; Ibáñez Domínguez, JÁ; Lara Almunia, M; Maimó Barceló, A; Pierola Lopetegui, J; Villalonga, P; Villalonga-Planells, R, 2019) |
| "Extent of resection of glioblastoma is an important predictor for overall survival, and 5-aminolevulinic acid fluorescence-guided surgery can improve outcomes." | 7.91 | Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma. ( Chan, KY; Gai, X; Ko, NMW; Law, M; Ng, BCF; Wong, HT; Woo, PYM, 2019) |
| "This novel proof-of-concept blue light-emitting headlamp device may offer an opportunity for institutions with limited resources to implement 5-aminolevulinic acid fluorescence-guided glioblastoma resections." | 7.91 | Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma. ( Chan, KY; Gai, X; Ko, NMW; Law, M; Ng, BCF; Wong, HT; Woo, PYM, 2019) |
| "This study is intended to objectively clarify the relationship between the fluorescence intensity emitted by protoporphyrin IX (PpIX), which is a metabolite of 5-aminolevulinic acid (ALA), and histological findings during glioblastoma surgery." | 7.88 | Spectral Radiance of Protoporphyrin IX Fluorescence and Its Histopathological Implications in 5-Aminolevulinic Acid-Guided Surgery for Glioblastoma. ( Furuse, M; Hirose, Y; Ikeda, N; Kajimoto, Y; Kawabata, S; Kuroiwa, T; Kuwabara, H; Nonoguchi, N; Tamura, Y; Yagi, R; Yoneda, T, 2018) |
| "In recent years, there is a growing evidence that using 5-aminolevulinic acid (5-ALA)-guided resection of a cerebral glioblastoma, associated with chemoradiotherapy determine a prolonged survival of these patients, even though this period do not exceed 15 months." | 7.85 | Longer survival of a patient with glioblastoma resected with 5-aminolevulinic acid (5-ALA)-guided surgery and foreign body reaction to polyglycolic acid (PGA) suture. ( DobrovăŢ, BI; Dumitrescu, N; Eva, L; Gavrilescu, CM; Iordache, AC; Mihăilă, D; Munteanu, RM; Pendefunda, L; Poeată, I; Şapte, E, 2017) |
| "The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM)." | 7.85 | Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. ( Berti, F; Cecchin, D; Della Puppa, A; Gardiman, MP; Lombardi, G; Persano, L; Rolma, G; Rossetto, M; Rustemi, O; Scienza, R; Zagonel, V, 2017) |
| "Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) is now a widely-used modality for glioblastoma (GBM) treatment." | 7.85 | Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma. ( Cho, HR; Choi, A; Choi, H; Choi, SH; Chowdhury, T; Dho, YS; Hwang, T; Kim, DG; Kim, H; Kim, HC; Kim, JE; Kim, JI; Kim, JW; Kim, S; Kim, SK; Kim, YH; Lee, SH; Park, CK; Park, S; Park, SH; Seo, Y; Shin, JY; Xu, WJ, 2017) |
| "The aim of this study was to identify preoperative factors (ie, age, enhancement, 18F-fluoroethyl tyrosine positron emission tomography [F-FET PET] uptake ratios) for predicting fluorescence in gliomas without typical glioblastomas imaging features and to determine whether fluorescence will allow prediction of tumor grade or molecular characteristics." | 7.83 | The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular ( Ewelt, C; Hasselblatt, M; Holling, M; Jaber, M; Niederstadt, T; Stummer, W; Weckesser, M; Wölfer, J; Zoubi, T, 2016) |
| "Glioblastoma resection guided by 5-aminolevulinic acid (5-ALA) fluorescence and intraoperative magnetic resonance imaging (iMRI) may improve surgical results and prolong survival." | 7.83 | Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation. ( Actor, B; Bernays, RL; Hauser, SB; Kockro, RA; Sarnthein, J, 2016) |
| "5-aminolevulinic acid (5-ALA) introduction in the surgical management of Glioblastoma (GBM) enables the intra-operatively identification of cancer cells in the mass by means of fluorescence." | 7.80 | Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery [corrected]. ( Basso, G; Battilana, G; Bianco, S; Della Puppa, A; Frasson, C; Persano, L; Rampazzo, E; Scienza, R, 2014) |
| "Thirty consecutive surgical patients with glioblastoma, were operated upon using fluorescence induced by 5-aminolevulinic acid as guidance." | 7.77 | Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. ( Díez Valle, R; Echeveste, J; Idoate, MA; Tejada, S, 2011) |
| " Here, we have studied the effect of 5-aminolevulinic acid (ALA)-mediated PDT on DCs in vitro in a human spheroid model of glioblastoma (GB)." | 7.77 | Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. ( Börger, V; Bünemann, E; Etminan, N; Hänggi, D; Lakbir, D; Peters, C; Sabel, MC; Sorg, RV; Steiger, HJ; Stummer, W, 2011) |
| "PpIX synthesis after incubation with delta-aminolevulinic acid (ALA) is highly variable from one cell to another within a single cell population and in human glioblastomas in vivo." | 7.70 | Protoporphyrin IX fluorescence kinetics in C6 glioblastoma cells after delta-aminolevulinic acid incubation: effect of a protoporphyrinogen oxidase inhibitor. ( Carre, J; Eleouet, S; Heyman, D; Lajat, Y; Patrice, T; Rousset, N; Vonarx, V, 1999) |
| "It has been established that 5-aminolevulinic acid (5-ALA) induces the accumulation of fluorescent porphyrins in glioblastoma multiforme (GBM), a phenomenon potentially exploitable to guide tumor resection." | 7.70 | Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. ( Bise, K; Goetz, C; Novotny, A; Reulen, HJ; Stepp, H; Stummer, W, 2000) |
| "Gliomas are diffuse intra-axial lesions, which can be accessed by multiple surgical corridors for a same location depending on the surgeon's preference." | 5.91 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 5.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "5-Aminolevulinic acid (5-ALA) is a naturally occurring non-proteinogenic amino acid, which contributes to the diagnosis and therapeutic approaches of various cancers, including glioblastoma (GBM)." | 5.62 | Antitumor Effects of 5-Aminolevulinic Acid on Human Malignant Glioblastoma Cells. ( Abbasinezhad-Moud, F; Etezad Razavi, M; Gorji, A; Jalili-Nik, M; Khaleghi Ghadiri, M; Maghrouni, A; Sahab-Negah, S; Stummer, W, 2021) |
| " 5-ALA was orally administered 3 hours before induction of anesthesia at a dosage of 20 mg/kg, whereas fluorescein was intravenously administered at induction of anesthesia at a dosage of 4 mg/kg." | 5.51 | Combined Fluorescence Using 5-Aminolevulinic Acid and Fluorescein Sodium at Glioblastoma Border: Intraoperative Findings and Histopathologic Data About 3 Newly Diagnosed Consecutive Cases. ( Della Puppa, A; Gardiman, MP; Munari, M; Volpin, F, 2019) |
| "5-Aminolevulinic acid (5-ALA) has become an important assistant in glioblastoma (GB) surgery." | 5.51 | Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma. ( Bestard Escalas, J; Brell Doval, M; Delgado Sánchez, O; Garfias Arjona, S; Ibáñez Domínguez, JÁ; Lara Almunia, M; Maimó Barceló, A; Pierola Lopetegui, J; Villalonga, P; Villalonga-Planells, R, 2019) |
| "5-Aminolevulinic acid /PDT-treated GB spheroids attracted DCs that acquired tumour antigens from the spheroids effectively." | 5.37 | Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. ( Börger, V; Bünemann, E; Etminan, N; Hänggi, D; Lakbir, D; Peters, C; Sabel, MC; Sorg, RV; Steiger, HJ; Stummer, W, 2011) |
| "Glioblastoma is the most common astrocytic brain tumor in humans." | 5.34 | 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells. ( Banik, NL; Karmakar, S; Patel, SJ; Ray, SK, 2007) |
| "5-Aminolevulinic acid (5-ALA) fluorescence can maximize perirolandic glioblastoma (GBM) resection with low rates of postoperative sequelae." | 5.22 | Functional outcomes, extent of resection, and bright/vague fluorescence interface in resection of glioblastomas involving the motor pathways assisted by 5-ALA. ( Bonaudo, C; Campagnaro, L; Carrai, R; Ciccarino, P; Dardo, M; Della Puppa, A; Esposito, A; Fainardi, E; Muscas, G; Orlandini, S, 2022) |
| "OBJECT There is evidence that 5-aminolevulinic acid (ALA) facilitates greater extent of resection and improves 6-month progression-free survival in patients with high-grade gliomas." | 5.22 | A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. ( Berger, MS; Chang, S; Hervey-Jumper, SL; Lau, D; McDermott, MW; Molinaro, AM; Phillips, JJ, 2016) |
| "Interstitial photodynamic therapy (iPDT) of non-resectable recurrent glioblastoma using 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) has shown a promising outcome." | 5.17 | Protoporphyrin IX fluorescence and photobleaching during interstitial photodynamic therapy of malignant gliomas for early treatment prognosis. ( Beyer, W; Egensperger, R; Faber, F; Johansson, A; Kniebühler, G; Kreth, FW; Sroka, R; Stepp, H, 2013) |
| "We analyzed the efficacy and applicability of surgery guided by 5-aminolevulinic acid (ALA) fluorescence in consecutive patients with glioblastoma multiforme (GBM)." | 5.15 | Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. ( Aristu Mendiroz, J; Díez Valle, R; Domínguez Echávarri, P; García de Eulate, R; Idoate Gastearena, MA; Tejada Solis, S, 2011) |
| "5-aminolevulinic acid (5-ALA) has been used for the last 5 years to increase the extent of resection in adult brain tumors, mostly glioblastomas, but it is not approved yet as standard adjuvant treatment in the pediatric population." | 4.90 | 5-ALA fluorescence-assisted surgery in pediatric brain tumors: report of three cases and review of the literature. ( Albanese, V; Barbagallo, GM; Certo, F; Heiss, K, 2014) |
| " This study is aimed to investigate the clinical availability of 5-aminolevulinic acid (5-ALA)-based PDD and PDT in glioblastoma (GBM) patient-derived tumorspheres (TSs) and mouse orthotopic xenograft model." | 4.31 | C5α secreted by tumor mesenchymal stem-like cells mediates resistance to 5-aminolevulinic acid-based photodynamic therapy against glioblastoma tumorspheres. ( Chang, JH; Huh, YM; Ji, YB; Kang, SG; Kim, EH; Lee, SJ; Moon, JH; Oh, SJ; Park, J; Shim, JK; Suh, JS, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 4.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "5-Aminolevulinic acid (5-ALA) fluorescence-guided resection of high-grade gliomas (HGG) increases the extent of resection (EOR) and progression-free survival." | 4.31 | Histology of high-grade glioma samples resected using 5-ALA fluorescent headlight and loupe combination. ( Giantini-Larsen, AM; Kharas, N; Pisapia, D; Schwartz, TH, 2023) |
| " established fluorescence-guided surgery (FGS) for glioblastoma (GBM) using 5-aminolevulinic acid (5-ALA)." | 4.12 | In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma. ( Geerling, G; Guthoff, R; Hänggi, D; Jeising, S; Nickel, AC; Rapp, M; Sabel, M, 2022) |
| "This study investigated the degree of tumor cell infiltration in the tumor cavity and ventricle wall based on fluorescent signals of 5-aminolevulinic acid (5-ALA) after removal of the magnetic resonance (MR)-enhancing area and analyzed its prognostic significance in glioblastoma." | 4.02 | Relationship between tumor cell infiltration and 5-aminolevulinic acid fluorescence signals after resection of MR-enhancing lesions and its prognostic significance in glioblastoma. ( Jang, W-; Jung, S; Jung, T-; Kim, I-; Kim, J-; Kim, S-; Lee, K-; Moon, K-, 2021) |
| "5-Aminolevulinic acid (5-ALA) is a naturally occurring non-proteinogenic amino acid, which contributes to the diagnosis and therapeutic approaches of various cancers, including glioblastoma (GBM)." | 4.02 | Antitumor Effects of 5-Aminolevulinic Acid on Human Malignant Glioblastoma Cells. ( Abbasinezhad-Moud, F; Etezad Razavi, M; Gorji, A; Jalili-Nik, M; Khaleghi Ghadiri, M; Maghrouni, A; Sahab-Negah, S; Stummer, W, 2021) |
| "Fluorescence-guided resection of glioblastomas (GBM) using 5-aminolevulinic acid (5-ALA) improves intraoperative tumor visualization and is thus widely used nowadays." | 3.96 | High Interobserver Agreement in the Subjective Classification of 5-Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas. ( Benner, D; Berger, MS; Borkovec, M; Hervey-Jumper, S; Hosmann, A; Kiesel, B; Knosp, E; Mischkulnig, M; Roessler, K; Wadiura, LI; Widhalm, G, 2020) |
| "The usefulness of 5-aminolevulinic acid (5-ALA)-mediated fluorescence-guided surgery (FGS) in meningiomas is intensely discussed." | 3.96 | Real-time in vivo kinetics of protoporphyrin IX after administration of 5-aminolevulinic acid in meningiomas and comparative analyses with glioblastomas. ( Brokinkel, B; Bunk, EC; Hess, K; Holling, M; Kaneko, S; Paulus, W; Senner, V; Stummer, W; Suero Molina, E; Warneke, N, 2020) |
| "In a previous study of photodynamic tumor diagnosis using 5-aminolevulinic acid (5-ALA), the authors proposed using fluorescence intensity and bright spot analyses under confocal microscopy for the precise discrimination of tumorous brain tissue (such as glioblastoma, GBM) from normal tissue." | 3.91 | Bright spot analysis for photodynamic diagnosis of brain tumors using confocal microscopy. ( Miyashita, K; Nakada, M; Tamai, S; Watanabe, T; Yoneyama, T, 2019) |
| "Although having shown promising clinical outcomes, the effectiveness of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) for squamous cell carcinoma (SCC) and glioblastoma remains to be improved." | 3.91 | Methadone enhances the effectiveness of 5-aminolevulinic acid-based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro. ( Buchner, A; Gederaas, OA; Pohla, H; Pongratz, T; Rühm, A; Shi, L; Sroka, R; Stepp, H; Wang, X; Zhang, L; Zimmermann, W, 2019) |
| "5-Aminolevulinic acid (5-ALA) has become an important assistant in glioblastoma (GB) surgery." | 3.91 | Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma. ( Bestard Escalas, J; Brell Doval, M; Delgado Sánchez, O; Garfias Arjona, S; Ibáñez Domínguez, JÁ; Lara Almunia, M; Maimó Barceló, A; Pierola Lopetegui, J; Villalonga, P; Villalonga-Planells, R, 2019) |
| "Extent of resection of glioblastoma is an important predictor for overall survival, and 5-aminolevulinic acid fluorescence-guided surgery can improve outcomes." | 3.91 | Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma. ( Chan, KY; Gai, X; Ko, NMW; Law, M; Ng, BCF; Wong, HT; Woo, PYM, 2019) |
| "This novel proof-of-concept blue light-emitting headlamp device may offer an opportunity for institutions with limited resources to implement 5-aminolevulinic acid fluorescence-guided glioblastoma resections." | 3.91 | Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma. ( Chan, KY; Gai, X; Ko, NMW; Law, M; Ng, BCF; Wong, HT; Woo, PYM, 2019) |
| "This study is intended to objectively clarify the relationship between the fluorescence intensity emitted by protoporphyrin IX (PpIX), which is a metabolite of 5-aminolevulinic acid (ALA), and histological findings during glioblastoma surgery." | 3.88 | Spectral Radiance of Protoporphyrin IX Fluorescence and Its Histopathological Implications in 5-Aminolevulinic Acid-Guided Surgery for Glioblastoma. ( Furuse, M; Hirose, Y; Ikeda, N; Kajimoto, Y; Kawabata, S; Kuroiwa, T; Kuwabara, H; Nonoguchi, N; Tamura, Y; Yagi, R; Yoneda, T, 2018) |
| "The extent of 5-aminolevulinic acid (5-ALA) guided tumor resection has a determining impact in high-grade glioma and glioblastoma surgery." | 3.85 | Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence. ( Burgio, F; Faia-Torres, AB; Fontana, AO; Marchi, F; Paganetti, P; Pieles, U; Piffaretti, D; Pinton, S; Reinert, M, 2017) |
| "In recent years, there is a growing evidence that using 5-aminolevulinic acid (5-ALA)-guided resection of a cerebral glioblastoma, associated with chemoradiotherapy determine a prolonged survival of these patients, even though this period do not exceed 15 months." | 3.85 | Longer survival of a patient with glioblastoma resected with 5-aminolevulinic acid (5-ALA)-guided surgery and foreign body reaction to polyglycolic acid (PGA) suture. ( DobrovăŢ, BI; Dumitrescu, N; Eva, L; Gavrilescu, CM; Iordache, AC; Mihăilă, D; Munteanu, RM; Pendefunda, L; Poeată, I; Şapte, E, 2017) |
| "The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM)." | 3.85 | Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. ( Berti, F; Cecchin, D; Della Puppa, A; Gardiman, MP; Lombardi, G; Persano, L; Rolma, G; Rossetto, M; Rustemi, O; Scienza, R; Zagonel, V, 2017) |
| "Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) is now a widely-used modality for glioblastoma (GBM) treatment." | 3.85 | Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma. ( Cho, HR; Choi, A; Choi, H; Choi, SH; Chowdhury, T; Dho, YS; Hwang, T; Kim, DG; Kim, H; Kim, HC; Kim, JE; Kim, JI; Kim, JW; Kim, S; Kim, SK; Kim, YH; Lee, SH; Park, CK; Park, S; Park, SH; Seo, Y; Shin, JY; Xu, WJ, 2017) |
| "The aim of this study was to identify preoperative factors (ie, age, enhancement, 18F-fluoroethyl tyrosine positron emission tomography [F-FET PET] uptake ratios) for predicting fluorescence in gliomas without typical glioblastomas imaging features and to determine whether fluorescence will allow prediction of tumor grade or molecular characteristics." | 3.83 | The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular ( Ewelt, C; Hasselblatt, M; Holling, M; Jaber, M; Niederstadt, T; Stummer, W; Weckesser, M; Wölfer, J; Zoubi, T, 2016) |
| "Glioblastoma resection guided by 5-aminolevulinic acid (5-ALA) fluorescence and intraoperative magnetic resonance imaging (iMRI) may improve surgical results and prolong survival." | 3.83 | Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation. ( Actor, B; Bernays, RL; Hauser, SB; Kockro, RA; Sarnthein, J, 2016) |
| " The prodrugs display reduced acute toxicity compared to 5-ALA-Hex with superior dose response profiles of protoporphyrin IX synthesis and fluorescence intensity in human glioblastoma cells in vitro." | 3.83 | Tunable phosphatase-sensitive stable prodrugs of 5-aminolevulinic acid for tumor fluorescence photodetection. ( Allémann, E; Ateb, I; Babič, A; Herceg, V; Lange, N, 2016) |
| "During 5-aminolevulinic acid (ALA)-guided glioblastoma multiforme (GBM) surgery, we encountered fluorescence in ventricular walls that lacked enhancement on magnetic resonance (MR) images and were free of macroscopic invasion of tumor cells." | 3.83 | Histopathological implications of ventricle wall 5-aminolevulinic acid-induced fluorescence in the absence of tumor involvement on magnetic resonance images. ( Chang, JH; Choi, J; Kang, SG; Kim, EH; Kim, SH; Lee, JH; Moon, JH; Park, J; Roh, TH; Shim, JK; Sung, KS, 2016) |
| " Recent studies revealed that 5-aminolevulinic acid (ALA)-based photodynamic therapy (PDT) has advantages over conventional treatments for glioblastoma." | 3.83 | Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model. ( Emmer, JV; Fahey, JM; Girotti, AW; Hogg, N; Korytowski, W, 2016) |
| "7h) PDT treatment in a nude mouse model of human glioblastoma by using organic light emitting diode (OLED) with single dose of 5-aminolevulinic acid (ALA) administration as photosensitizer." | 3.81 | Low-fluence rate, long duration photodynamic therapy in glioma mouse model using organic light emitting diode (OLED). ( Chen, PH; Chiou, SH; Dong, CY; Guo, HW; Ho, MH; Hsieh, YS; Huang, WT; Lee, YJ; Lin, LT; Wang, HW, 2015) |
| "5-aminolevulinic acid (5-ALA) introduction in the surgical management of Glioblastoma (GBM) enables the intra-operatively identification of cancer cells in the mass by means of fluorescence." | 3.80 | Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery [corrected]. ( Basso, G; Battilana, G; Bianco, S; Della Puppa, A; Frasson, C; Persano, L; Rampazzo, E; Scienza, R, 2014) |
| "Fluorescence-guided microsurgical resections of high-grade gliomas using 5-aminolevulinic acid (5-ALA) is superior to conventional microsurgery." | 3.80 | Fluorescence-guided surgery in high grade gliomas using an exoscope system. ( Belloch, JP; Cremades, A; Llácer, JL; Riesgo, PA; Rovira, V, 2014) |
| "Cultured glioblastoma D54Mg cells were photosensitized with 5-aminolevulinic acid so that cell survival was 95-100%." | 3.78 | Dynamics of signaling, cytoskeleton and cell cycle regulation proteins in glioblastoma cells after sub-lethal photodynamic treatment: antibody microarray study. ( Juzeniene, A; Kristiansen, B; Moan, J; Uzdensky, A, 2012) |
| "Thirty consecutive surgical patients with glioblastoma, were operated upon using fluorescence induced by 5-aminolevulinic acid as guidance." | 3.77 | Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. ( Díez Valle, R; Echeveste, J; Idoate, MA; Tejada, S, 2011) |
| " Here, we have studied the effect of 5-aminolevulinic acid (ALA)-mediated PDT on DCs in vitro in a human spheroid model of glioblastoma (GB)." | 3.77 | Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. ( Börger, V; Bünemann, E; Etminan, N; Hänggi, D; Lakbir, D; Peters, C; Sabel, MC; Sorg, RV; Steiger, HJ; Stummer, W, 2011) |
| " In recent clinical studies, fluorescence monitoring during iPDT of glioblastoma multiforme has revealed patient-specific accumulation of photosensitizer (aminolevulinic acid (ALA) induced protoporphyrin IX, PpIX) and its photobleaching kinetics." | 3.77 | Photobleaching-based method to individualize irradiation time during interstitial 5-aminolevulinic acid photodynamic therapy. ( Hennig, G; Johansson, A; Stepp, H, 2011) |
| " It is shown that sublethal PDT of human WiDr adenocarcinoma cells and D54Mg glioblastoma cells with 5-aminolevulinic acid (ALA), disulfonated tetraphenylporphyrine (TPPS(2a)), or MitoTracker Red (MTR) inhibits their trypsin-induced detachment from a plastic substratum." | 3.72 | Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum. ( Juzeniene, A; Ma, LW; Moan, J; Uzdensky, A, 2004) |
| "PpIX synthesis after incubation with delta-aminolevulinic acid (ALA) is highly variable from one cell to another within a single cell population and in human glioblastomas in vivo." | 3.70 | Protoporphyrin IX fluorescence kinetics in C6 glioblastoma cells after delta-aminolevulinic acid incubation: effect of a protoporphyrinogen oxidase inhibitor. ( Carre, J; Eleouet, S; Heyman, D; Lajat, Y; Patrice, T; Rousset, N; Vonarx, V, 1999) |
| "It has been established that 5-aminolevulinic acid (5-ALA) induces the accumulation of fluorescent porphyrins in glioblastoma multiforme (GBM), a phenomenon potentially exploitable to guide tumor resection." | 3.70 | Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. ( Bise, K; Goetz, C; Novotny, A; Reulen, HJ; Stepp, H; Stummer, W, 2000) |
| "Patients with suspected high-grade brain tumors are given 5-ALA 4 h prior to stereotactic biopsy." | 2.77 | 5-Aminolevulinic acid-induced protoporphyrin IX fluorescence as immediate intraoperative indicator to improve the safety of malignant or high-grade brain tumor diagnosis in frameless stereotactic biopsies. ( Hefti, M; Moschopulos, M; von Campe, G, 2012) |
| "Eighteen patients with primary malignant brain tumors in eloquent areas were included in this prospective study." | 2.75 | Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. ( Bornemann, A; Danz, S; Feigl, GC; Gharabaghi, A; Klein, J; Krischek, B; Liebsch, M; Moraes, M; Ramina, K; Ritz, R; Tatagiba, MS, 2010) |
| "5-aminolevulinic acid (5-ALA) has been used for the last 5 years to increase the extent of resection in adult brain tumors, mostly glioblastomas, but it is not approved yet as standard adjuvant treatment in the pediatric population." | 2.50 | 5-ALA fluorescence-assisted surgery in pediatric brain tumors: report of three cases and review of the literature. ( Albanese, V; Barbagallo, GM; Certo, F; Heiss, K, 2014) |
| "Gliomas are the most common primary brain tumors and result in dismal outcomes when present at high grades." | 2.48 | Fluorescence-guided malignant glioma resections. ( Adamson, DC; Babu, R, 2012) |
| "Surgical removal of glioblastomas is challenging due to their infiltrative growth pattern." | 2.45 | [Fluorescence guided resection of malignant brain tumors - breakthrough in the surgery of brain tumors]. ( Cadosch, D; Fournier, JY; Gautschi, OP; Hildebrandt, G; van Leyen, K, 2009) |
| "Gliomas are diffuse intra-axial lesions, which can be accessed by multiple surgical corridors for a same location depending on the surgeon's preference." | 1.91 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| " We measured GICs-5-ALA uptake and PDT/5-ALA activity in dose-response curves and the efficacy of the treatment by measuring proliferative activity and apoptosis." | 1.91 | Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy. ( Aldecoa, I; Bedia, C; Centellas, M; Diao, D; Ferrés, A; González Sánchez, JJ; Martínez-Soler, F; Mosteiro, A; Muñoz-Tudurí, M; Pedrosa, L; Pineda, E; Sevilla, A; Sierra, À; Stanzani, E; Tortosa, A, 2023) |
| "Glioblastoma multiforme is an aggressive type of brain cancer with high recurrence rates due to the presence of radioresistant cells remaining after tumor resection." | 1.91 | Combining Pr ( Bietar, K; Capobianco, JA; Mandl, GA; Maurizio, SL; Stochaj, U; Tessitore, G; Vettier, F, 2023) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 1.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "Thus, RDT is expected to enhance RT treatment of glioblastoma without severe toxicity under clinically feasible conditions." | 1.62 | In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy. ( Doi, M; Ikemoto, MJ; Iwahashi, H; Nagasawa, S; Narita, Y; Takahashi, J; Takahashi, M; Yamamoto, J, 2021) |
| "Glioblastoma is the most severe form of brain cancer." | 1.62 | Isolation and initial characterization of human glioblastoma cells resistant to photodynamic therapy. ( Caputto, BL; Caverzán, MD; Milla Sanabria, LN; Palacios, RE; Prucca, CG; Rivarola, VA; Rodríguez, LB; Vilchez, ML, 2021) |
| "We simulate our algorithm on virtual brain tumors modeling real glioblastoma multiforme cases, assuming a 5-ALA PpIX induced photosensitizer that is activated at [Formula: see text] wavelength." | 1.62 | Optimizing Interstitial Photodynamic Therapy Planning With Reinforcement Learning-Based Diffuser Placement. ( Betz, V; Lilge, L; Yassine, AA, 2021) |
| "5-Aminolevulinic acid (5-ALA) is a naturally occurring non-proteinogenic amino acid, which contributes to the diagnosis and therapeutic approaches of various cancers, including glioblastoma (GBM)." | 1.62 | Antitumor Effects of 5-Aminolevulinic Acid on Human Malignant Glioblastoma Cells. ( Abbasinezhad-Moud, F; Etezad Razavi, M; Gorji, A; Jalili-Nik, M; Khaleghi Ghadiri, M; Maghrouni, A; Sahab-Negah, S; Stummer, W, 2021) |
| "Glioblastoma is the most common primary brain tumor; survival is typically 12-18 months after diagnosis." | 1.56 | Investigation of the tumoricidal effects of sonodynamic therapy in malignant glioblastoma brain tumors. ( Moore, D; Padilla, F; Sheehan, D; Sheehan, J; Sheehan, K; Sulaiman, M; Xu, Z, 2020) |
| "The challenge in the treatment of glioblastoma is the failure to identify the cancer invasive area outside the contrast-enhancing tumour which leads to the high local progression rate." | 1.56 | A Neural Network Approach to Identify the Peritumoral Invasive Areas in Glioblastoma Patients by Using MR Radiomics. ( Boonzaier, NR; Li, C; Matys, T; Price, SJ; van der Hoorn, A; Yan, JL, 2020) |
| "5-Aminolevulinic acid (20 mg/kg) was given 4 h before surgery." | 1.56 | Endoscopic Fluorescence-Guided Resection Increases Radicality in Glioblastoma Surgery. ( Behme, D; Bettag, C; Hussein, A; Maragkou, T; Mielke, D; Rohde, V, 2020) |
| "Sensitivity and specificity were calculated for Gd-DTPA MRI, PWI, met-PET, and 5-ALA according to the histology of specimen." | 1.51 | Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and ( Beer, AJ; Coburger, J; Eberhardt, N; König, R; Pala, A; Reske, SN; Scheuerle, A; Schmitz, B; Wirtz, CR, 2019) |
| " 5-ALA was orally administered 3 hours before induction of anesthesia at a dosage of 20 mg/kg, whereas fluorescein was intravenously administered at induction of anesthesia at a dosage of 4 mg/kg." | 1.51 | Combined Fluorescence Using 5-Aminolevulinic Acid and Fluorescein Sodium at Glioblastoma Border: Intraoperative Findings and Histopathologic Data About 3 Newly Diagnosed Consecutive Cases. ( Della Puppa, A; Gardiman, MP; Munari, M; Volpin, F, 2019) |
| "5-Aminolevulinic acid (5-ALA) has become an important assistant in glioblastoma (GB) surgery." | 1.51 | Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma. ( Bestard Escalas, J; Brell Doval, M; Delgado Sánchez, O; Garfias Arjona, S; Ibáñez Domínguez, JÁ; Lara Almunia, M; Maimó Barceló, A; Pierola Lopetegui, J; Villalonga, P; Villalonga-Planells, R, 2019) |
| "Microscopic detection of intracranial brain tumors with 5-aminolevulinic acid (5-ALA) has proven extremely useful, and reports the use of 5-ALA have recently increased." | 1.48 | Neuroendoscopic Cylinder Surgery and 5-Aminolevulinic Acid Photodynamic Diagnosis of Deep-Seated Intracranial Lesions. ( Choo, J; Kato, K; Kishida, Y; Nagata, Y; Nagatani, T; Natsume, A; Ohka, F; Satoh, Y; Takeuchi, K; Wakabayashi, T; Watanabe, T, 2018) |
| "Gefitinib treatment was able to restore fluorescence after EGF stimulation in U87MG cells but not in BS153 cells, overexpressing EGFR/EGFRvIII." | 1.46 | Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence. ( Burgio, F; Faia-Torres, AB; Fontana, AO; Marchi, F; Paganetti, P; Pieles, U; Piffaretti, D; Pinton, S; Reinert, M, 2017) |
| "Glioblastoma is a high-grade cerebral tumor with local recurrence and poor outcome." | 1.46 | Interstitial photodynamic therapy and glioblastoma: Light fractionation in a preclinical model. ( Duhamel, A; Leroux, B; Leroy, HA; Maurage, CA; Mordon, S; Reyns, N; Vermandel, M; Vignion-Dewalle, AS, 2017) |
| "Glioblastoma, a WHO grade IV astrocytoma, is a highly aggressive and heterogeneous tumour that infiltrates deeply into surrounding brain parenchyma, making complete surgical resection impossible." | 1.46 | The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour. ( Chhaya, S; Diksin, M; Estevez-Cebrero, MA; Rahman, R; Sairam, S; Smith, SJ, 2017) |
| "5-Aminolevulinic acid (5-ALA) has been at the forefront of small molecule based fluorescence-guided tumor resection and photodynamic therapy." | 1.43 | Tunable phosphatase-sensitive stable prodrugs of 5-aminolevulinic acid for tumor fluorescence photodetection. ( Allémann, E; Ateb, I; Babič, A; Herceg, V; Lange, N, 2016) |
| "Mean residual tumor volume (range) after iMRI-assisted surgery [0." | 1.40 | Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. ( Bisdas, S; Ebner, FH; Ernemann, U; Honegger, J; Naegele, T; Roder, C; Tatagiba, M, 2014) |
| "Analysis of residual tumor volumes, total resections and neurological outcomes demonstrate that iMRI may be significantly superior to 5-ALA and white-light surgery for glioblastomas at comparable peri- and postoperative morbidities." | 1.40 | Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. ( Bisdas, S; Ebner, FH; Ernemann, U; Honegger, J; Naegele, T; Roder, C; Tatagiba, M, 2014) |
| "Histology revealed pilocytic astrocytoma (n = 7), classical medulloblastoma (n = 4), anaplastic astrocytoma (n = 1), glioblastoma (n = 3) and anaplastic ependymoma (n = 1)." | 1.40 | Fluorescence-guided surgery with 5-aminolevulinic acid for resection of brain tumors in children--a technical report. ( Beez, T; Hänggi, D; Sarikaya-Seiwert, S; Steiger, HJ, 2014) |
| "As for the two biopsy cases, one was anaplastic astrocytoma and one glioblastoma multiforme." | 1.40 | Fluorescence-guided surgery in high grade gliomas using an exoscope system. ( Belloch, JP; Cremades, A; Llácer, JL; Riesgo, PA; Rovira, V, 2014) |
| "5-aminolevulinic acid (5-ALA) is a pro-drug that leads to accumulation of fluorescent protoporphyrins in malignant gliomas." | 1.38 | Fluorescence-guided resection of gliomas. ( Cortnum, S; Laursen, RJ, 2012) |
| "All four patients who developed hydrocephalus had periventricular tumours and the ventricle wall had been opened during surgery." | 1.38 | Prognostic value of ventricular wall fluorescence during 5-aminolevulinic-guided surgery for glioblastoma. ( Aldave-Orzaiz, G; Díez-Valle, R; Idoate-Gastearena, MA; Marigil-Sánchez, M; Pay-Valverde, E; Tejada-Solís, S, 2012) |
| "5-Aminolevulinic acid /PDT-treated GB spheroids attracted DCs that acquired tumour antigens from the spheroids effectively." | 1.37 | Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. ( Börger, V; Bünemann, E; Etminan, N; Hänggi, D; Lakbir, D; Peters, C; Sabel, MC; Sorg, RV; Steiger, HJ; Stummer, W, 2011) |
| "In most cases, glioblastoma are characterized by a constitutive activation of NF-κB." | 1.37 | 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. ( Agostinis, P; Coupienne, I; Fettweis, G; Piette, J; Rubio, N, 2011) |
| "Glioblastoma were previously shown to respond to treatments by 5-aminolevulinic acid (5-ALA)-based photodynamic therapy (PDT) mainly by activating a necrotic type of cell death." | 1.37 | 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. ( Agostinis, P; Coupienne, I; Fettweis, G; Piette, J; Rubio, N, 2011) |
| "Five-aminolevulinic acid (ALA) is a drug which induces protoporphyrin IX accumulation in malignant gliomas and has been explored for fluorescence-guided resections of these tumors." | 1.35 | Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. ( Baumgartner, R; Beck, T; Beyer, W; Etminan, N; Herms, J; Kreth, FW; Mehrkens, JH; Obermeier, A; Stepp, H; Stummer, W; Tonn, JC, 2008) |
| "Glioblastoma is the most common astrocytic brain tumor in humans." | 1.34 | 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells. ( Banik, NL; Karmakar, S; Patel, SJ; Ray, SK, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.20) | 18.2507 |
| 2000's | 14 (8.43) | 29.6817 |
| 2010's | 107 (64.46) | 24.3611 |
| 2020's | 43 (25.90) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, J | 1 |
| Nagasawa, S | 1 |
| Doi, M | 1 |
| Takahashi, M | 1 |
| Narita, Y | 1 |
| Yamamoto, J | 1 |
| Ikemoto, MJ | 1 |
| Iwahashi, H | 1 |
| Ebrahimpour, A | 1 |
| Tirgar, F | 1 |
| Hajipour-Verdom, B | 1 |
| Abbasi, A | 1 |
| Hadjighassem, M | 1 |
| Abdolmaleki, P | 1 |
| Hosseindoost, S | 1 |
| Javadi, SAH | 1 |
| Hashemi, H | 1 |
| Foroushani, AR | 1 |
| Alam, NR | 1 |
| Khoobi, M | 1 |
| Werner, M | 1 |
| Lyu, C | 1 |
| Stadlbauer, B | 1 |
| Schrader, I | 1 |
| Buchner, A | 2 |
| Stepp, H | 8 |
| Sroka, R | 4 |
| Pohla, H | 2 |
| Jeising, S | 1 |
| Geerling, G | 1 |
| Guthoff, R | 1 |
| Hänggi, D | 3 |
| Sabel, M | 3 |
| Rapp, M | 3 |
| Nickel, AC | 1 |
| Muscas, G | 1 |
| Orlandini, S | 1 |
| Bonaudo, C | 1 |
| Dardo, M | 1 |
| Esposito, A | 1 |
| Campagnaro, L | 1 |
| Carrai, R | 1 |
| Fainardi, E | 1 |
| Ciccarino, P | 1 |
| Della Puppa, A | 5 |
| Park, J | 2 |
| Oh, SJ | 1 |
| Shim, JK | 2 |
| Ji, YB | 1 |
| Moon, JH | 2 |
| Kim, EH | 2 |
| Huh, YM | 1 |
| Suh, JS | 1 |
| Chang, JH | 2 |
| Lee, SJ | 1 |
| Kang, SG | 2 |
| Altieri, R | 1 |
| Broggi, G | 1 |
| Certo, F | 2 |
| Pacella, D | 1 |
| Cammarata, G | 1 |
| Maione, M | 1 |
| Garozzo, M | 1 |
| Barbagallo, D | 1 |
| Purrello, M | 1 |
| Caltabiano, R | 1 |
| Magro, G | 1 |
| Barbagallo, G | 1 |
| Plaha, P | 3 |
| Camp, S | 3 |
| Cook, J | 3 |
| McCulloch, P | 3 |
| Voets, N | 3 |
| Ma, R | 4 |
| Taphoorn, MJB | 3 |
| Dirven, L | 3 |
| Grech-Sollars, M | 3 |
| Watts, C | 5 |
| Bulbeck, H | 3 |
| Jenkinson, MD | 3 |
| Williams, M | 4 |
| Lim, A | 3 |
| Dixon, L | 3 |
| Price, SJ | 6 |
| Ashkan, K | 3 |
| Apostolopoulos, V | 3 |
| Barber, VS | 3 |
| Taylor, A | 3 |
| Nandi, D | 3 |
| Hsia, T | 3 |
| Yekula, A | 3 |
| Batool, SM | 3 |
| Rosenfeld, YB | 3 |
| You, DG | 3 |
| Weissleder, R | 3 |
| Lee, H | 3 |
| Carter, BS | 3 |
| Balaj, L | 3 |
| Devalckeneer, A | 2 |
| Aboukaïs, R | 2 |
| Bourgeois, P | 2 |
| Reyns, N | 7 |
| Lejeune, JP | 4 |
| Giantini-Larsen, AM | 1 |
| Kharas, N | 1 |
| Pisapia, D | 1 |
| Schwartz, TH | 1 |
| Witten, AJ | 1 |
| Ben-Shalom, N | 1 |
| Ellis, JA | 1 |
| Boockvar, JA | 1 |
| D'Amico, RS | 2 |
| Quach, S | 1 |
| Schwartz, C | 1 |
| Aumiller, M | 1 |
| Foglar, M | 1 |
| Schmutzer, M | 1 |
| Katzendobler, S | 1 |
| El Fahim, M | 1 |
| Forbrig, R | 1 |
| Bochmann, K | 1 |
| Egensperger, R | 2 |
| Rühm, A | 2 |
| Thon, N | 1 |
| Pedrosa, L | 1 |
| Bedia, C | 1 |
| Diao, D | 1 |
| Mosteiro, A | 1 |
| Ferrés, A | 1 |
| Stanzani, E | 1 |
| Martínez-Soler, F | 1 |
| Tortosa, A | 1 |
| Pineda, E | 1 |
| Aldecoa, I | 1 |
| Centellas, M | 1 |
| Muñoz-Tudurí, M | 1 |
| Sevilla, A | 1 |
| Sierra, À | 1 |
| González Sánchez, JJ | 1 |
| Mandl, GA | 1 |
| Vettier, F | 1 |
| Tessitore, G | 1 |
| Maurizio, SL | 1 |
| Bietar, K | 1 |
| Stochaj, U | 1 |
| Capobianco, JA | 1 |
| Keenlyside, A | 1 |
| Marples, T | 1 |
| Gao, Z | 1 |
| Hu, H | 1 |
| Nicely, LG | 1 |
| Nogales, J | 1 |
| Li, H | 1 |
| Landgraf, L | 1 |
| Solth, A | 1 |
| Melzer, A | 1 |
| Hossain-Ibrahim, K | 1 |
| Huang, Z | 1 |
| Banerjee, S | 1 |
| Joseph, J | 1 |
| Piffaretti, D | 2 |
| Burgio, F | 2 |
| Thelen, M | 1 |
| Kaelin-Lang, A | 1 |
| Paganetti, P | 2 |
| Reinert, M | 2 |
| D'Angelo, ML | 1 |
| Kamp, MA | 3 |
| Cornelius, JF | 2 |
| Knipps, J | 1 |
| Müller, M | 1 |
| von Saß, C | 1 |
| Mijderwijk, HJ | 1 |
| Steiger, HJ | 5 |
| Sabel, MC | 4 |
| Woo, PYM | 2 |
| Gai, X | 2 |
| Wong, HT | 2 |
| Chan, KY | 2 |
| Potapov, AA | 1 |
| Chobulov, SA | 1 |
| Nikitin, PV | 1 |
| Okhlopkov, VA | 1 |
| Goryaynov, SA | 1 |
| Kosyr'kova, AV | 1 |
| Maryakhin, AD | 1 |
| Chelushkin, DM | 1 |
| Ryzhova, MV | 1 |
| Zakharova, NE | 1 |
| Batalov, AI | 1 |
| Pronin, IN | 1 |
| Danilov, GV | 1 |
| Savel'eva, TA | 1 |
| Loshchenov, VB | 1 |
| Yashin, KS | 1 |
| Chekhonin, VP | 1 |
| Mischkulnig, M | 1 |
| Kiesel, B | 2 |
| Borkovec, M | 1 |
| Wadiura, LI | 1 |
| Benner, D | 1 |
| Hosmann, A | 1 |
| Hervey-Jumper, S | 1 |
| Knosp, E | 2 |
| Roessler, K | 2 |
| Berger, MS | 4 |
| Widhalm, G | 2 |
| Brem, S | 1 |
| Henderson, F | 1 |
| Sheehan, K | 1 |
| Sheehan, D | 1 |
| Sulaiman, M | 1 |
| Padilla, F | 1 |
| Moore, D | 1 |
| Sheehan, J | 1 |
| Xu, Z | 1 |
| Kaneko, S | 1 |
| Brokinkel, B | 1 |
| Suero Molina, E | 1 |
| Warneke, N | 1 |
| Holling, M | 2 |
| Bunk, EC | 1 |
| Hess, K | 1 |
| Senner, V | 1 |
| Paulus, W | 2 |
| Stummer, W | 10 |
| Teh, DBL | 1 |
| Bansal, A | 1 |
| Chai, C | 1 |
| Toh, TB | 1 |
| Tucker, RAJ | 1 |
| Gammad, GGL | 1 |
| Yeo, Y | 1 |
| Lei, Z | 1 |
| Zheng, X | 1 |
| Yang, F | 1 |
| Ho, JS | 1 |
| Bolem, N | 1 |
| Wu, BC | 1 |
| Gnanasammandhan, MK | 1 |
| Hooi, L | 1 |
| Dawe, GS | 1 |
| Libedinsky, C | 1 |
| Ong, WY | 1 |
| Halliwell, B | 1 |
| Chow, EK | 1 |
| Lim, KL | 1 |
| Zhang, Y | 1 |
| Kennedy, BK | 1 |
| Cho, SS | 1 |
| Sheikh, S | 1 |
| Teng, CW | 1 |
| Georges, J | 1 |
| Yang, AI | 1 |
| De Ravin, E | 1 |
| Buch, L | 1 |
| Li, C | 2 |
| Singh, Y | 1 |
| Appelt, D | 1 |
| Delikatny, EJ | 1 |
| Petersson, EJ | 1 |
| Tsourkas, A | 1 |
| Dorsey, J | 1 |
| Singhal, S | 1 |
| Lee, JYK | 1 |
| Yan, JL | 2 |
| van der Hoorn, A | 2 |
| Boonzaier, NR | 2 |
| Matys, T | 3 |
| Napier, TS | 1 |
| Udayakumar, N | 1 |
| Jani, AH | 1 |
| Hartman, YE | 1 |
| Houson, HA | 1 |
| Moore, L | 1 |
| Amm, HM | 1 |
| van den Berg, NS | 1 |
| Sorace, AG | 1 |
| Warram, JM | 1 |
| Kim, J- | 2 |
| Jung, T- | 1 |
| Jung, S | 1 |
| Kim, I- | 1 |
| Jang, W- | 1 |
| Moon, K- | 1 |
| Kim, S- | 1 |
| Lee, K- | 1 |
| Mastrangelopoulou, M | 1 |
| Grigalavicius, M | 1 |
| Raabe, TH | 1 |
| Skarpen, E | 1 |
| Juzenas, P | 1 |
| Peng, Q | 1 |
| Berg, K | 1 |
| Theodossiou, TA | 1 |
| Müller, P | 1 |
| Abdel Gaber, SA | 1 |
| Zimmermann, W | 2 |
| Wittig, R | 1 |
| Bajaj, J | 1 |
| Yadav, YR | 1 |
| Vilchez, ML | 1 |
| Rodríguez, LB | 1 |
| Palacios, RE | 1 |
| Prucca, CG | 1 |
| Caverzán, MD | 1 |
| Caputto, BL | 1 |
| Rivarola, VA | 1 |
| Milla Sanabria, LN | 1 |
| Bettag, C | 2 |
| Schregel, K | 1 |
| Langer, P | 1 |
| Thomas, C | 1 |
| Behme, D | 2 |
| Stadelmann, C | 1 |
| Rohde, V | 3 |
| Mielke, D | 2 |
| Strickland, BA | 1 |
| Zada, G | 1 |
| Yassine, AA | 1 |
| Lilge, L | 1 |
| Betz, V | 1 |
| Vermandel, M | 5 |
| Dupont, C | 2 |
| Lecomte, F | 2 |
| Leroy, HA | 5 |
| Tuleasca, C | 1 |
| Mordon, S | 5 |
| Hadjipanayis, CG | 4 |
| Jalili-Nik, M | 1 |
| Abbasinezhad-Moud, F | 1 |
| Sahab-Negah, S | 1 |
| Maghrouni, A | 1 |
| Etezad Razavi, M | 1 |
| Khaleghi Ghadiri, M | 1 |
| Gorji, A | 1 |
| Shono, K | 1 |
| Mizobuchi, Y | 1 |
| Yamaguchi, I | 1 |
| Nakajima, K | 1 |
| Fujiwara, Y | 1 |
| Fujihara, T | 1 |
| Kitazato, K | 1 |
| Matsuzaki, K | 1 |
| Uto, Y | 1 |
| Sampetrean, O | 1 |
| Saya, H | 1 |
| Takagi, Y | 1 |
| Nikova, AS | 1 |
| Vlotinou, P | 1 |
| Karelis, L | 1 |
| Karanikas, M | 1 |
| Birbilis, TA | 1 |
| Yano, H | 1 |
| Nakayama, N | 1 |
| Ohe, N | 1 |
| Miwa, K | 1 |
| Shinoda, J | 1 |
| Iwama, T | 1 |
| Fontana, AO | 1 |
| Marchi, F | 1 |
| Faia-Torres, AB | 1 |
| Pinton, S | 1 |
| Pieles, U | 1 |
| Picart, T | 2 |
| Armoiry, X | 3 |
| Berthiller, J | 1 |
| Dumot, C | 1 |
| Pelissou-Guyotat, I | 2 |
| Signorelli, F | 1 |
| Guyotat, J | 4 |
| Munteanu, RM | 1 |
| Eva, L | 1 |
| DobrovăŢ, BI | 1 |
| Iordache, AC | 1 |
| Pendefunda, L | 1 |
| Dumitrescu, N | 1 |
| Mihăilă, D | 1 |
| Gavrilescu, CM | 1 |
| Şapte, E | 1 |
| Poeată, I | 1 |
| Waqas, M | 1 |
| Khan, I | 1 |
| Shamim, MS | 1 |
| Sage, W | 1 |
| Guilfoyle, M | 1 |
| Luney, C | 1 |
| Young, A | 1 |
| Sinha, R | 1 |
| Sgubin, D | 1 |
| McAbee, JH | 1 |
| Jefferies, S | 1 |
| Jena, R | 1 |
| Harris, F | 1 |
| Allinson, K | 1 |
| Qian, W | 1 |
| Santarius, T | 1 |
| Price, S | 1 |
| Ross, JL | 1 |
| Cooper, LAD | 1 |
| Kong, J | 1 |
| Gutman, D | 1 |
| Tucker-Burden, C | 1 |
| McCrary, MR | 1 |
| Bouras, A | 1 |
| Kaluzova, M | 1 |
| Dunn, WD | 1 |
| Duong, D | 1 |
| Brat, DJ | 1 |
| Roux, A | 1 |
| Zanello, M | 1 |
| Pallud, J | 2 |
| Choo, J | 1 |
| Takeuchi, K | 1 |
| Nagata, Y | 1 |
| Ohka, F | 1 |
| Kishida, Y | 1 |
| Watanabe, T | 2 |
| Satoh, Y | 1 |
| Nagatani, T | 1 |
| Kato, K | 1 |
| Wakabayashi, T | 1 |
| Natsume, A | 1 |
| Pala, A | 2 |
| Reske, SN | 1 |
| Eberhardt, N | 1 |
| Scheuerle, A | 3 |
| König, R | 4 |
| Schmitz, B | 1 |
| Beer, AJ | 1 |
| Wirtz, CR | 4 |
| Coburger, J | 4 |
| Fujishiro, T | 1 |
| Nonoguchi, N | 3 |
| Pavliukov, M | 1 |
| Ohmura, N | 1 |
| Kawabata, S | 2 |
| Park, Y | 1 |
| Kajimoto, Y | 3 |
| Ishikawa, T | 2 |
| Nakano, I | 2 |
| Kuroiwa, T | 3 |
| Quidet, M | 1 |
| Delhem, N | 1 |
| Kröger, S | 1 |
| Niehoff, AC | 1 |
| Jeibmann, A | 1 |
| Sperling, M | 1 |
| Karst, U | 1 |
| Yamashita, M | 1 |
| Osaki, T | 1 |
| Sunden, Y | 1 |
| Takahashi, K | 2 |
| Ishizuka, M | 1 |
| Tanaka, T | 1 |
| Li, L | 1 |
| Okamoto, Y | 1 |
| Munari, M | 1 |
| Gardiman, MP | 2 |
| Volpin, F | 1 |
| Michael, AP | 1 |
| Watson, VL | 1 |
| Ryan, D | 1 |
| Delfino, KR | 1 |
| Bekker, SV | 1 |
| Cozzens, JW | 1 |
| Yoneyama, T | 1 |
| Tamai, S | 1 |
| Miyashita, K | 1 |
| Nakada, M | 2 |
| de Laurentis, C | 1 |
| Del Bene, M | 1 |
| Fociani, P | 1 |
| Tonello, C | 1 |
| Pollo, B | 1 |
| DiMeco, F | 1 |
| Millesi, M | 1 |
| Wöhrer, A | 1 |
| Mercea, PA | 1 |
| Bissolo, M | 1 |
| Roetzer, T | 1 |
| Wolfsberger, S | 1 |
| Furtner, J | 1 |
| Hussein, A | 1 |
| Maragkou, T | 1 |
| Shi, L | 1 |
| Pongratz, T | 1 |
| Gederaas, OA | 1 |
| Zhang, L | 1 |
| Wang, X | 1 |
| Garfias Arjona, S | 1 |
| Lara Almunia, M | 1 |
| Ibáñez Domínguez, JÁ | 1 |
| Delgado Sánchez, O | 1 |
| Villalonga, P | 1 |
| Villalonga-Planells, R | 1 |
| Pierola Lopetegui, J | 1 |
| Bestard Escalas, J | 1 |
| Maimó Barceló, A | 1 |
| Brell Doval, M | 1 |
| Müther, M | 1 |
| Koch, R | 1 |
| Weckesser, M | 2 |
| Sporns, P | 1 |
| Schwindt, W | 1 |
| Giordano, M | 1 |
| Gallieni, M | 1 |
| Zaed, I | 1 |
| Samii, A | 1 |
| Cage, TA | 1 |
| Pekmezci, M | 1 |
| Prados, M | 1 |
| Langen, KJ | 1 |
| Floeth, FW | 1 |
| Galldiks, N | 1 |
| Pastor, J | 1 |
| Pulido-Rivas, P | 1 |
| Sola, RG | 1 |
| Johansson, A | 2 |
| Faber, F | 1 |
| Kniebühler, G | 1 |
| Beyer, W | 2 |
| Kreth, FW | 2 |
| Aldave, G | 1 |
| Tejada, S | 3 |
| Pay, E | 1 |
| Marigil, M | 1 |
| Bejarano, B | 1 |
| Idoate, MA | 2 |
| Díez-Valle, R | 4 |
| Tejada-Solis, S | 2 |
| Suzuki, T | 2 |
| Wada, S | 1 |
| Eguchi, H | 1 |
| Adachi, J | 1 |
| Mishima, K | 1 |
| Matsutani, M | 1 |
| Nishikawa, R | 1 |
| Nishiyama, M | 1 |
| Rampazzo, E | 2 |
| Frasson, C | 1 |
| Battilana, G | 1 |
| Bianco, S | 1 |
| Scienza, R | 2 |
| Basso, G | 1 |
| Persano, L | 3 |
| Roder, C | 2 |
| Bisdas, S | 2 |
| Ebner, FH | 1 |
| Honegger, J | 1 |
| Naegele, T | 1 |
| Ernemann, U | 1 |
| Tatagiba, M | 2 |
| Schucht, P | 4 |
| Knittel, S | 1 |
| Slotboom, J | 1 |
| Seidel, K | 3 |
| Murek, M | 3 |
| Jilch, A | 2 |
| Raabe, A | 4 |
| Beck, J | 4 |
| Beez, T | 1 |
| Sarikaya-Seiwert, S | 1 |
| Belloch, JP | 1 |
| Rovira, V | 1 |
| Llácer, JL | 1 |
| Riesgo, PA | 1 |
| Cremades, A | 1 |
| Engelke, J | 1 |
| Thal, DR | 1 |
| Hlavac, M | 1 |
| Barbagallo, GM | 1 |
| Heiss, K | 1 |
| Albanese, V | 1 |
| Albert, I | 1 |
| Hefti, M | 2 |
| Luginbuehl, V | 1 |
| De Vleeschouwer, S | 1 |
| Wiest, R | 1 |
| Fung, C | 1 |
| Felsberg, J | 2 |
| Sadat, H | 1 |
| Kuzibaev, J | 1 |
| Reifenberger, G | 1 |
| Dibué, M | 1 |
| Moiyadi, AV | 2 |
| Sridhar, E | 2 |
| Guo, HW | 1 |
| Lin, LT | 1 |
| Chen, PH | 1 |
| Ho, MH | 1 |
| Huang, WT | 1 |
| Lee, YJ | 1 |
| Chiou, SH | 1 |
| Hsieh, YS | 1 |
| Dong, CY | 1 |
| Wang, HW | 1 |
| Hagel, V | 1 |
| Corns, R | 1 |
| Mukherjee, S | 1 |
| Johansen, A | 1 |
| Sivakumar, G | 1 |
| Tetard, MC | 1 |
| Leroux, B | 2 |
| Maurage, CA | 2 |
| Jaber, M | 1 |
| Wölfer, J | 1 |
| Ewelt, C | 2 |
| Hasselblatt, M | 1 |
| Niederstadt, T | 1 |
| Zoubi, T | 1 |
| Hauser, SB | 2 |
| Kockro, RA | 2 |
| Actor, B | 1 |
| Sarnthein, J | 1 |
| Bernays, RL | 2 |
| Cordova, JS | 2 |
| Gurbani, SS | 2 |
| Holder, CA | 2 |
| Olson, JJ | 2 |
| Schreibmann, E | 2 |
| Shi, R | 1 |
| Guo, Y | 1 |
| Shu, HK | 2 |
| Shim, H | 2 |
| Pavlov, V | 1 |
| Metellus, P | 1 |
| Lau, D | 1 |
| Hervey-Jumper, SL | 1 |
| Chang, S | 1 |
| Molinaro, AM | 1 |
| McDermott, MW | 1 |
| Phillips, JJ | 1 |
| Lawrence, JE | 1 |
| Steele, CJ | 1 |
| Rovin, RA | 1 |
| Belton, RJ | 1 |
| Winn, RJ | 1 |
| Quick-Weller, J | 1 |
| Lescher, S | 1 |
| Forster, MT | 1 |
| Konczalla, J | 1 |
| Seifert, V | 1 |
| Senft, C | 1 |
| Ju, D | 1 |
| Yamaguchi, F | 1 |
| Zhan, G | 1 |
| Higuchi, T | 1 |
| Asakura, T | 1 |
| Morita, A | 1 |
| Orimo, H | 1 |
| Hu, S | 1 |
| Alexiou, GA | 1 |
| Vartholomatos, G | 1 |
| Voulgaris, S | 1 |
| Kyritsis, AP | 1 |
| Liang, Z | 1 |
| Cooper, LA | 1 |
| Kairdolf, B | 1 |
| Neill, SG | 1 |
| Larkin, TJ | 1 |
| Babič, A | 1 |
| Herceg, V | 1 |
| Ateb, I | 1 |
| Allémann, E | 1 |
| Lange, N | 1 |
| Kim, SH | 2 |
| Roh, TH | 1 |
| Sung, KS | 1 |
| Lee, JH | 1 |
| Choi, J | 1 |
| Schimanski, A | 2 |
| Ebbert, L | 1 |
| Finocchiaro, G | 1 |
| Lamszus, K | 1 |
| Etminan, N | 4 |
| Fischer, JC | 1 |
| Sorg, RV | 3 |
| Fahey, JM | 1 |
| Emmer, JV | 1 |
| Korytowski, W | 1 |
| Hogg, N | 1 |
| Girotti, AW | 1 |
| Shetty, P | 1 |
| Lombardi, G | 1 |
| Rossetto, M | 1 |
| Rustemi, O | 2 |
| Berti, F | 1 |
| Cecchin, D | 1 |
| Rolma, G | 1 |
| Zagonel, V | 1 |
| Vignion-Dewalle, AS | 1 |
| Duhamel, A | 1 |
| Thal, D | 1 |
| Pichlmeier, U | 1 |
| Bink, A | 1 |
| Schackert, G | 1 |
| Gautschi, OP | 1 |
| van Leyen, K | 1 |
| Cadosch, D | 1 |
| Hildebrandt, G | 1 |
| Fournier, JY | 1 |
| Feigl, GC | 1 |
| Ritz, R | 2 |
| Moraes, M | 1 |
| Klein, J | 1 |
| Ramina, K | 1 |
| Gharabaghi, A | 1 |
| Krischek, B | 1 |
| Danz, S | 1 |
| Bornemann, A | 1 |
| Liebsch, M | 1 |
| Tatagiba, MS | 1 |
| Haj-Hosseini, N | 1 |
| Richter, J | 1 |
| Andersson-Engels, S | 1 |
| Wårdell, K | 1 |
| Díez Valle, R | 2 |
| Tejada Solis, S | 1 |
| Idoate Gastearena, MA | 1 |
| García de Eulate, R | 1 |
| Domínguez Echávarri, P | 1 |
| Aristu Mendiroz, J | 1 |
| Coupienne, I | 2 |
| Bontems, S | 1 |
| Dewaele, M | 1 |
| Rubio, N | 2 |
| Habraken, Y | 1 |
| Fulda, S | 1 |
| Agostinis, P | 2 |
| Piette, J | 2 |
| Tanaka, S | 1 |
| Hayashi, Y | 2 |
| Nakada, S | 1 |
| Sawada-Kitamura, S | 1 |
| Furuyama, N | 1 |
| Kamide, T | 1 |
| Yano, S | 1 |
| Hamada, J | 1 |
| Kostron, H | 1 |
| Bauer, R | 1 |
| Echeveste, J | 1 |
| Berkovitch-Luria, G | 1 |
| Weitman, M | 1 |
| Nudelman, A | 1 |
| Rephaeli, A | 1 |
| Malik, Z | 1 |
| Biggs, T | 1 |
| Foreman, J | 1 |
| Sundstrom, L | 1 |
| Regenass, U | 1 |
| Lehembre, F | 1 |
| Ikeda, N | 2 |
| Miyatake, S | 1 |
| Hagiya, Y | 1 |
| Ogura, S | 1 |
| Nakagawa, H | 1 |
| Peters, C | 2 |
| Lakbir, D | 1 |
| Bünemann, E | 1 |
| Börger, V | 2 |
| Hennig, G | 1 |
| Samkoe, KS | 1 |
| Gibbs-Strauss, SL | 1 |
| Yang, HH | 1 |
| Khan Hekmatyar, S | 1 |
| Jack Hoopes, P | 1 |
| O'Hara, JA | 1 |
| Kauppinen, RA | 1 |
| Pogue, BW | 1 |
| Fettweis, G | 1 |
| von Campe, G | 1 |
| Moschopulos, M | 1 |
| Babu, R | 1 |
| Adamson, DC | 1 |
| Nestler, U | 1 |
| Warter, A | 1 |
| Cabre, P | 1 |
| Manzo, N | 1 |
| Becherer, A | 1 |
| Donat, M | 1 |
| Cejna, M | 1 |
| Zachenhofer, I | 1 |
| Uzdensky, A | 2 |
| Kristiansen, B | 1 |
| Moan, J | 2 |
| Juzeniene, A | 2 |
| Santacroce, A | 1 |
| Zella, S | 1 |
| Reichelt, DC | 1 |
| Piccirillo, SG | 1 |
| Dietz, S | 1 |
| Madhu, B | 1 |
| Griffiths, J | 1 |
| Collins, VP | 1 |
| Roberts, DW | 1 |
| Valdés, PA | 1 |
| Harris, BT | 1 |
| Hartov, A | 1 |
| Fan, X | 1 |
| Ji, S | 1 |
| Leblond, F | 1 |
| Tosteson, TD | 1 |
| Wilson, BC | 1 |
| Paulsen, KD | 1 |
| Wachter, D | 1 |
| Kallenberg, K | 1 |
| Wrede, A | 1 |
| Schulz-Schaeffer, W | 1 |
| Behm, T | 1 |
| Cortnum, S | 1 |
| Laursen, RJ | 1 |
| Abu-Isa, J | 1 |
| Andereggen, L | 1 |
| Stieglitz, L | 1 |
| Aldave-Orzaiz, G | 1 |
| Pay-Valverde, E | 1 |
| Marigil-Sánchez, M | 1 |
| Idoate-Gastearena, MA | 1 |
| Smith, LG | 1 |
| Jacquesson, T | 1 |
| Ducray, F | 1 |
| Maucort-Boulch, D | 1 |
| Louis-Tisserand, G | 1 |
| Mbaye, M | 1 |
| Vogel, S | 1 |
| Madsen, SJ | 2 |
| Sun, CH | 2 |
| Tromberg, BJ | 2 |
| Hirschberg, H | 2 |
| Ma, LW | 1 |
| Duffner, F | 1 |
| Freudenstein, D | 1 |
| Weller, M | 1 |
| Dietz, K | 1 |
| Wessels, J | 1 |
| Sailer, R | 1 |
| Strauss, WS | 2 |
| Wagner, M | 1 |
| Emmert, H | 1 |
| Schneckenburger, H | 2 |
| Karmakar, S | 1 |
| Banik, NL | 1 |
| Patel, SJ | 1 |
| Ray, SK | 1 |
| Lassalle, HP | 1 |
| Baumann, H | 1 |
| Eljamel, MS | 1 |
| Goodman, C | 1 |
| Moseley, H | 1 |
| Beck, T | 1 |
| Mehrkens, JH | 1 |
| Obermeier, A | 1 |
| Tonn, JC | 1 |
| Baumgartner, R | 1 |
| Herms, J | 1 |
| Luckers, O | 1 |
| James, S | 1 |
| Ghassempour, K | 1 |
| Maertens de Noordhout, A | 1 |
| Born, JD | 1 |
| Helson, L | 1 |
| Braverman, S | 1 |
| Mangiardi, J | 1 |
| Carre, J | 2 |
| Eleouet, S | 2 |
| Rousset, N | 2 |
| Vonarx, V | 2 |
| Heyman, D | 1 |
| Lajat, Y | 2 |
| Patrice, T | 2 |
| Vilatte, C | 1 |
| Louët, C | 1 |
| Wallace, VP | 1 |
| Novotny, A | 1 |
| Goetz, C | 1 |
| Bise, K | 1 |
| Reulen, HJ | 1 |
| Law, M | 1 |
| Ng, BCF | 1 |
| Ko, NMW | 1 |
| Della Pepa, GM | 1 |
| Ius, T | 1 |
| La Rocca, G | 1 |
| Gaudino, S | 1 |
| Isola, M | 1 |
| Pignotti, F | 1 |
| Rapisarda, A | 1 |
| Mazzucchi, E | 1 |
| Giordano, C | 1 |
| Dragonetti, V | 1 |
| Chiesa, S | 1 |
| Balducci, M | 1 |
| Gessi, M | 1 |
| Skrap, M | 1 |
| Olivi, A | 1 |
| Marchese, E | 1 |
| Sabatino, G | 1 |
| Dadario, NB | 1 |
| Khatri, D | 1 |
| Reichman, N | 1 |
| Nwagwu, CD | 1 |
| Kim, S | 1 |
| Kim, JE | 1 |
| Kim, YH | 1 |
| Hwang, T | 1 |
| Kim, SK | 1 |
| Xu, WJ | 1 |
| Shin, JY | 1 |
| Kim, JI | 1 |
| Choi, H | 1 |
| Kim, HC | 1 |
| Cho, HR | 1 |
| Choi, A | 1 |
| Chowdhury, T | 1 |
| Seo, Y | 1 |
| Dho, YS | 1 |
| Kim, JW | 1 |
| Kim, DG | 1 |
| Park, SH | 1 |
| Kim, H | 1 |
| Choi, SH | 1 |
| Park, S | 1 |
| Lee, SH | 1 |
| Park, CK | 1 |
| Smith, SJ | 1 |
| Diksin, M | 1 |
| Chhaya, S | 1 |
| Sairam, S | 1 |
| Estevez-Cebrero, MA | 1 |
| Rahman, R | 1 |
| Yoneda, T | 1 |
| Yagi, R | 1 |
| Furuse, M | 1 |
| Hirose, Y | 1 |
| Kuwabara, H | 1 |
| Tamura, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot/Feasibility Study of Intraoperative Image-Guided Surgery of CNS Tumors With Indocyanine Green and MR Spectroscopic Imaging[NCT02710240] | Phase 1/Phase 2 | 336 participants (Actual) | Interventional | 2015-06-10 | Completed | ||
| A Pilot Study of the Feasibility of Intraoperative Photodynamic Therapy of Glioblastoma.[NCT03048240] | 10 participants (Actual) | Interventional | 2017-05-05 | Completed | |||
| 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas[NCT05850377] | 90 participants (Anticipated) | Observational | 2023-06-01 | Not yet recruiting | |||
| Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors[NCT02740933] | Phase 1 | 40 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation With Preoperative MR, ALA-induced PpIX Fluorescence, and Histopathology[NCT02691923] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
sensitivity of delayed, high dose indocyanine green (second window ICG), as measured by the signal-to-background ratio (SBR) (NCT02710240)
Timeframe: 72 hours
| Intervention | ratio (Mean) |
|---|---|
| ICG Arm | 5.49 |
12 reviews available for aminolevulinic acid and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Functional outcomes, extent of resection, and bright/vague fluorescence interface in resection of glioblastomas involving the motor pathways assisted by 5-ALA.
Topics: Aminolevulinic Acid; Brain Neoplasms; Efferent Pathways; Glioblastoma; Humans; Neoplasm, Residual; R | 2022 |
Gross total resection with fluorescence could lead to improved overall survival rates: a systematic review and meta-analysis.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescein; Glioblastoma; Humans; Survival Rate | 2022 |
Role of 5-ALA in improving extent of tumour resection in patients with Glioblastoma Multiforme.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Glioblastoma; Humans; Image Interpretation, Computer-As | 2017 |
5-ALA fluorescence-assisted surgery in pediatric brain tumors: report of three cases and review of the literature.
Topics: Adolescent; Aminolevulinic Acid; Brain Neoplasms; Child; Female; Fluorescence; Glioblastoma; Humans; | 2014 |
Fluorescence guided resection and glioblastoma in 2015: A review.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Photosensitizing Agents; P | 2015 |
5-Aminolevulinic Acid-Protoporphyrin IX Fluorescence-Guided Surgery of High-Grade Gliomas: A Systematic Review.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Microscopy, Fluores | 2016 |
[Fluorescence guided resection of malignant brain tumors - breakthrough in the surgery of brain tumors].
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Magnetic Resonance Imaging | 2009 |
Management of recurrent malignant glioma--neurosurgical strategies.
Topics: Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Microscopy, F | 2011 |
Fluorescence-guided malignant glioma resections.
Topics: Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Fluorescent Dyes; Glioblastoma; Hum | 2012 |
Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid).
Topics: Aminolevulinic Acid; Brain Neoplasms; Disease-Free Survival; Fluorescent Dyes; Glioblastoma; Humans; | 2012 |
[Surgery of high-grade gliomas guided by fluorescence: a retrospective study of 22 patients].
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Brain | 2013 |
5-Aminolevulinic Acid-Shedding Light on Where to Focus.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans; Image Enhancement; Levulinic Acids; Micr | 2021 |
13 trials available for aminolevulinic acid and Astrocytoma, Grade IV
| Article | Year |
|---|---|
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma - a two-stage randomised control trial.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Neuronavigation; Quality of Life; Ultrasonography, Interv | 2022 |
Evaluation of Diagnostic Accuracy Following the Coadministration of Delta-Aminolevulinic Acid and Second Window Indocyanine Green in Rodent and Human Glioblastomas.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Flu | 2020 |
Effects of 5-ALA dose on resection of glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Contrast Media; Dose-Response | 2019 |
Protoporphyrin IX fluorescence and photobleaching during interstitial photodynamic therapy of malignant gliomas for early treatment prognosis.
Topics: Adult; Aged; Aminolevulinic Acid; Biomarkers; Biopsy; Brain; Brain Neoplasms; Female; Fluorescence; | 2013 |
Semi-Automated Volumetric and Morphological Assessment of Glioblastoma Resection with Fluorescence-Guided Surgery.
Topics: Adult; Aged; Aminolevulinic Acid; Automation; Brain Neoplasms; Disease-Free Survival; Endpoint Deter | 2016 |
A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas.
Topics: Aminolevulinic Acid; Biopsy; Brain; Brain Neoplasms; Cell Count; Female; Glioblastoma; Glioma; Human | 2016 |
Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.
Topics: Adolescent; Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblasto | 2008 |
Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.
Topics: Adolescent; Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblasto | 2008 |
Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.
Topics: Adolescent; Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblasto | 2008 |
Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.
Topics: Adolescent; Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblasto | 2008 |
Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring.
Topics: Adult; Aged; Aminolevulinic Acid; Astrocytoma; Brain Neoplasms; Cerebral Cortex; Combined Modality T | 2010 |
Optical touch pointer for fluorescence guided glioblastoma resection using 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Brain Neoplasms; Equipment Design; Glioblastoma; Humans; Lasers; Photobleaching | 2010 |
Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Humans; Immun | 2011 |
5-Aminolevulinic acid-induced protoporphyrin IX fluorescence as immediate intraoperative indicator to improve the safety of malignant or high-grade brain tumor diagnosis in frameless stereotactic biopsies.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy, Needle; Brain Neoplasms; Female; Gliobl | 2012 |
ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial.
Topics: Aminolevulinic Acid; Dihematoporphyrin Ether; Disease Progression; Female; Glioblastoma; Humans; Kar | 2008 |
Heterogeneity of delta-aminolevulinic acid-induced protoporphyrin IX fluorescence in human glioma cells and leukemic lymphocytes.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Brain Neoplasms; Female; Glioblastoma; | 2000 |
141 other studies available for aminolevulinic acid and Astrocytoma, Grade IV
| Article | Year |
|---|---|
In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therap | 2021 |
Detection of glioblastoma multiforme using quantitative molecular magnetic resonance imaging based on 5-aminolevulinic acid: in vitro and in vivo studies.
Topics: Aminolevulinic Acid; Animals; Glioblastoma; Iron; Magnetic Resonance Imaging; Rats; Rats, Wistar | 2022 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neopl | 2022 |
In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Photochemotherapy; Photosensiti | 2022 |
C5α secreted by tumor mesenchymal stem-like cells mediates resistance to 5-aminolevulinic acid-based photodynamic therapy against glioblastoma tumorspheres.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Glioblastoma; Humans; Mice; Photochemotherapy; Photo | 2023 |
Anatomical distribution of cancer stem cells between enhancing nodule and FLAIR hyperintensity in supratentorial glioblastoma: time to recalibrate the surgical target?
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplastic St | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Glioblastoma-derived extracellular vesicle subpopulations following 5-aminolevulinic acid treatment bear diagnostic implications.
Topics: Aminolevulinic Acid; Extracellular Vesicles; Glioblastoma; Humans | 2022 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Histology of high-grade glioma samples resected using 5-ALA fluorescent headlight and loupe combination.
Topics: Aminolevulinic Acid; Brain Neoplasms; Coloring Agents; Glioblastoma; Glioma; Humans; Surgery, Comput | 2023 |
Optimization of novel exoscopic blue light filter during fluorescence-guided resection of Glioblastoma.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Neurosurgical Procedures; | 2023 |
Interstitial photodynamic therapy for newly diagnosed glioblastoma.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; DNA Modification Methylases; Glioblastoma; Humans; Photo | 2023 |
Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Cell Line, Tumor; Coculture Techniques; Glioblastoma; G | 2023 |
Combining Pr
Topics: Aminolevulinic Acid; Cell Line, Tumor; Glioblastoma; Humans; Photochemotherapy; X-Rays | 2023 |
Development and optimisation of in vitro sonodynamic therapy for glioblastoma.
Topics: Aminolevulinic Acid; Apoptosis; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Reactive Oxygen Spec | 2023 |
Protoporphyrin IX tracer fluorescence modulation for improved brain tumor cell lines visualization.
Topics: Aminolevulinic Acid; ATP Binding Cassette Transporter, Subfamily G, Member 2; Brain Neoplasms; Cell | 2019 |
Letter to the Editor Regarding "A Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma".
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans | 2020 |
In Reply to the Letter to the Editor Regarding "A Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma."
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans | 2020 |
[Intraoperative vascular fluorescence in cerebral glioblastomas and vascular histological features].
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Middle Aged; | 2019 |
High Interobserver Agreement in the Subjective Classification of 5-Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas.
Topics: Aminolevulinic Acid; Cohort Studies; Glioblastoma; Humans; Observer Variation | 2020 |
Commentary: 5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the 2 Techniques to Optimize the Extent of Resection in Glioblastoma Surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans | 2020 |
Investigation of the tumoricidal effects of sonodynamic therapy in malignant glioblastoma brain tumors.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Glioblast | 2020 |
Real-time in vivo kinetics of protoporphyrin IX after administration of 5-aminolevulinic acid in meningiomas and comparative analyses with glioblastomas.
Topics: Aminolevulinic Acid; Fluorescence; Glioblastoma; Humans; Kinetics; Meningeal Neoplasms; Meningioma; | 2020 |
A Flexi-PEGDA Upconversion Implant for Wireless Brain Photodynamic Therapy.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Gl | 2020 |
A Neural Network Approach to Identify the Peritumoral Invasive Areas in Glioblastoma Patients by Using MR Radiomics.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Cohort Studies; Contrast Media; Diffusion Magneti | 2020 |
Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents, Immunological; Female; Glioblastoma; Humans; Mi | 2020 |
Relationship between tumor cell infiltration and 5-aminolevulinic acid fluorescence signals after resection of MR-enhancing lesions and its prognostic significance in glioblastoma.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Cell Movement; Cerebral Ventricles; DNA Modification Met | 2021 |
Predictive biomarkers for 5-ALA-PDT can lead to personalized treatments and overcome tumor-specific resistances.
Topics: Aminolevulinic Acid; Biomarkers; Glioblastoma; Humans; Photochemotherapy; Photosensitizing Agents | 2022 |
ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells.
Topics: Aminolevulinic Acid; ATP Binding Cassette Transporter, Subfamily G, Member 2; Brain Neoplasms; Cell | 2020 |
Letter: 5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans; Ultrasonography | 2020 |
Isolation and initial characterization of human glioblastoma cells resistant to photodynamic therapy.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Glioblastoma; Humans; Neoplasm Recurrence, Local; Photochemot | 2021 |
Endoscope-assisted fluorescence-guided resection allowing supratotal removal in glioblastoma surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans; Magnetic Resonance Imaging; Retrospectiv | 2021 |
5-ALA Enhanced Fluorescence-Guided Microscopic to Endoscopic Resection of Deep Frontal Subcortical Glioblastoma Multiforme.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans; Male; Microsurgery; Neuroendoscopy | 2021 |
Optimizing Interstitial Photodynamic Therapy Planning With Reinforcement Learning-Based Diffuser Placement.
Topics: Algorithms; Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans; Photochemotherapy; Photosens | 2021 |
Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial.
Topics: Aminolevulinic Acid; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Glioblast | 2021 |
Antitumor Effects of 5-Aminolevulinic Acid on Human Malignant Glioblastoma Cells.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Brain Ne | 2021 |
Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma stem cell-bearing glioma model by downregulating the Akt/NF-κB/MDR1 pathway.
Topics: Aminolevulinic Acid; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tu | 2021 |
Pathological analysis of the surgical margins of resected glioblastomas excised using photodynamic visualization with both 5-aminolevulinic acid and fluorescein sodium.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescein; Glioblastoma; Humans; Ki-67 | 2017 |
Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Topics: Aminolevulinic Acid; Astrocytes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Fluoresc | 2017 |
Is fluorescence-guided surgery with 5-ala in eloquent areas for malignant gliomas a reasonable and useful technique?
Topics: Adult; Aged; Aminolevulinic Acid; Brain Mapping; Brain Neoplasms; Disease-Free Survival; Female; Flu | 2017 |
Longer survival of a patient with glioblastoma resected with 5-aminolevulinic acid (5-ALA)-guided surgery and foreign body reaction to polyglycolic acid (PGA) suture.
Topics: Aminolevulinic Acid; Brain; Glioblastoma; Humans; Male; Middle Aged; Polyglycolic Acid; Survival Ana | 2017 |
Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Gliobla | 2018 |
5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins.
Topics: Adult; Aged; Aminolevulinic Acid; ErbB Receptors; Female; Fluorescence; Glioblastoma; Humans; Male; | 2017 |
Letter to the editor: local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans | 2018 |
Neuroendoscopic Cylinder Surgery and 5-Aminolevulinic Acid Photodynamic Diagnosis of Deep-Seated Intracranial Lesions.
Topics: Adolescent; Adult; Aged; Aminolevulinic Acid; Astrocytoma; Biopsy; Brain Neoplasms; Child; Female; G | 2018 |
Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Gadolinium DTPA; Glioblastoma; Humans; Ma | 2019 |
5-Aminolevulinic acid-mediated photodynamic therapy can target human glioma stem-like cells refractory to antineoplastic agents.
Topics: AC133 Antigen; Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gl | 2018 |
INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): Study Protocol for a Phase I Clinical Trial.
Topics: Adult; Aminolevulinic Acid; Brain Neoplasms; Clinical Protocols; Combined Modality Therapy; Female; | 2019 |
Complementary Molecular and Elemental Mass-Spectrometric Imaging of Human Brain Tumors Resected by Fluorescence-Guided Surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Laser Therapy; Mass Spectr | 2018 |
Photodynamic detection of a canine glioblastoma using 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Brain; Brain Neoplasms; Dog Diseases; Dogs; Fluorescence; Glioblastoma | 2020 |
Combined Fluorescence Using 5-Aminolevulinic Acid and Fluorescein Sodium at Glioblastoma Border: Intraoperative Findings and Histopathologic Data About 3 Newly Diagnosed Consecutive Cases.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescein; Fluorescent Dyes; Glioblastoma; Humans; M | 2019 |
Bright spot analysis for photodynamic diagnosis of brain tumors using confocal microscopy.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Male; Microscopy, Confoc | 2019 |
5-ALA Fluorescence in Case of Brain Abscess by Aggregatibacter Mimicking Glioblastoma.
Topics: Aggregatibacter; Aminolevulinic Acid; Brain Abscess; Brain Neoplasms; Diagnosis, Differential; Gliob | 2019 |
Is Intraoperative Pathology Needed if 5-Aminolevulinic-Acid-Induced Tissue Fluorescence Is Found in Stereotactic Brain Tumor Biopsy?
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Brain Neoplasms; Female; Fluorescence; | 2020 |
Endoscopic Fluorescence-Guided Resection Increases Radicality in Glioblastoma Surgery.
Topics: Aged; Aminolevulinic Acid; Brain; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; | 2020 |
Methadone enhances the effectiveness of 5-aminolevulinic acid-based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro.
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Drug Synergi | 2019 |
Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Costs and Cost Analysis; Glioblastoma; Human | 2019 |
5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma.
Topics: Aminolevulinic Acid; Brain Neoplasms; Gadolinium; Glioblastoma; Humans; Optical Imaging; Positron-Em | 2019 |
Use of Frameless Stereotactic Navigation System Combined with Intraoperative Magnetic Resonance Imaging and 5-Aminolevulinic Acid.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Humans; Intra | 2019 |
Subependymal spread of recurrent glioblastoma detected with the intraoperative use of 5-aminolevulinic acid: case report.
Topics: Aminolevulinic Acid; Diagnosis, Differential; Glioblastoma; Glioma, Subependymal; Humans; Intraopera | 2013 |
Sensitivity of intraoperative 5-aminolevulinic acid fluorescence compared with PET using O-(2-¹⁸F-fluoroethyl)-L-tyrosine to detect cerebral gliomas.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescent Dyes; Glioblastoma; Humans; Male; Monitori | 2013 |
[Neurophysiological assisted transsulcal approach to a high grade glioma without affect neither motor nor somatosensory function].
Topics: Adult; Aminolevulinic Acid; Anesthesia, Intravenous; Brain Mapping; Craniotomy; Evoked Potentials, S | 2013 |
Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescent Dyes; Glioblastoma; Humans; Kaplan-Meier E | 2013 |
Diffuse glioma detection.
Topics: Aminolevulinic Acid; Glioblastoma; Glioma, Subependymal; Humans; Male; Neoplasm Recurrence, Local; O | 2013 |
Cadherin 13 overexpression as an important factor related to the absence of tumor fluorescence in 5-aminolevulinic acid-guided resection of glioma.
Topics: Aminolevulinic Acid; Biomarkers; Brain Neoplasms; Cadherins; Cell Line, Tumor; Fluorescence; Gene Ex | 2013 |
Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery [corrected].
Topics: AC133 Antigen; Aminolevulinic Acid; Antigens, CD; Biopsy; Brain Neoplasms; Flow Cytometry; Glioblast | 2014 |
Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Cohort Studies; Disease-Free S | 2014 |
5-ALA complete resections go beyond MR contrast enhancement: shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Humans; Magneti | 2014 |
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of brain tumors in children--a technical report.
Topics: Adolescent; Aminolevulinic Acid; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Feasibility | 2014 |
Fluorescence-guided surgery in high grade gliomas using an exoscope system.
Topics: Adult; Aged; Aminolevulinic Acid; Astrocytoma; Biopsy; Brain Neoplasms; Female; Fluorescent Dyes; Gl | 2014 |
Tumor detection with 5-aminolevulinic acid fluorescence and Gd-DTPA-enhanced intraoperative MRI at the border of contrast-enhancing lesions: a prospective study based on histopathological assessment.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Contrast Media; Female; Fluore | 2014 |
Use of 5-aminolevulinic acid helps see the way beyond MRI.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Gadolinium DTPA; Glioblastoma; Humans; Magnetic Resona | 2014 |
Results expected in 5-ALA-guided resection of glioblastoma.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2014 |
Reply to the letter to the editor called: results expected in 5-ALA-guided resection of glioblastoma.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2014 |
Physiological oxygen concentration alters glioma cell malignancy and responsiveness to photodynamic therapy in vitro.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents, Phytogenic; Camptothecin; Caspase 3; Cell Culture | 2014 |
Letter: Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2014 |
Intraoperative monopolar mapping during 5-ALA-guided resections of glioblastomas adjacent to motor eloquent areas: evaluation of resection rates and neurological outcome.
Topics: Acoustic Stimulation; Aminolevulinic Acid; Brain Mapping; Brain Neoplasms; Electroencephalography; E | 2014 |
5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Disease Progression; Female; Fluorescence; Glioblastoma; | 2015 |
Δ-aminolevulinic acid-induced fluorescence unmasks biological intratumoral heterogeneity within histologically homogeneous areas of malignant gliomas.
Topics: Aminolevulinic Acid; Astrocytoma; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Neurosurgical | 2015 |
Response to: "Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery".
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2015 |
Low-fluence rate, long duration photodynamic therapy in glioma mouse model using organic light emitting diode (OLED).
Topics: Aminolevulinic Acid; Animals; Disease Models, Animal; Glioblastoma; Humans; Mice; Mice, Nude; Photoc | 2015 |
Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Case-Control Studies; Glioblastoma; Humans; Magne | 2015 |
5-aminolevulinic acid guidance during awake craniotomy to maximise extent of safe resection of glioblastoma multiforme.
Topics: Adult; Aminolevulinic Acid; Brain; Brain Neoplasms; Craniotomy; Female; Fluorescence; Glioblastoma; | 2015 |
Interstitial 5-ALA photodynamic therapy and glioblastoma: Preclinical model development and preliminary results.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Cell Line, Tumor; Dose Fractionation, Radiation; Dose | 2016 |
The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Female; | 2016 |
Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation.
Topics: Adult; Aged; Aminolevulinic Acid; Biopsy; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Human | 2016 |
Commentary: Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Magnetic Resonance Imaging | 2016 |
Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.
Topics: Aminolevulinic Acid; Anti-Inflammatory Agents; Anticonvulsants; Desipramine; Dexamethasone; Drug The | 2016 |
Combination of 5-ALA and iMRI in re-resection of recurrent glioblastoma.
Topics: Adult; Aged; Aminolevulinic Acid; Brain; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Res | 2016 |
Hyperthermotherapy enhances antitumor effect of 5-aminolevulinic acid-mediated sonodynamic therapy with activation of caspase-dependent apoptotic pathway in human glioma.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Combined M | 2016 |
In Reply: Glioblastoma Resection Guided by Flow Cytometry.
Topics: Aminolevulinic Acid; Brain Neoplasms; Flow Cytometry; Glioblastoma; Humans | 2016 |
Letter: Glioblastoma Resection Guided by Flow Cytometry.
Topics: Aminolevulinic Acid; Brain Neoplasms; Flow Cytometry; Glioblastoma; Humans | 2016 |
Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.
Topics: Aminolevulinic Acid; Aspartic Acid; Biomarkers; Brain; Brain Neoplasms; Cell Count; Choline; Disease | 2016 |
Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients.
Topics: Adult; Aged; Aminolevulinic Acid; Biomarkers, Tumor; Brain; Contrast Media; Diffusion Tensor Imaging | 2017 |
Tunable phosphatase-sensitive stable prodrugs of 5-aminolevulinic acid for tumor fluorescence photodetection.
Topics: Alkaline Phosphatase; Aminolevulinic Acid; Animals; Brain Neoplasms; Cell Line, Tumor; Chick Embryo; | 2016 |
Histopathological implications of ventricle wall 5-aminolevulinic acid-induced fluorescence in the absence of tumor involvement on magnetic resonance images.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Glioma; Humans; Magn | 2016 |
Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Syner | 2016 |
Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model.
Topics: Adjuvants, Pharmaceutic; Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; G | 2016 |
Periventricular glioblastomas and ependymal involvement interrogated using intraoperative fluorescence - a pathological correlative study.
Topics: Adult; Aged; Aminolevulinic Acid; Cerebral Ventricle Neoplasms; Ependyma; Female; Fluorescence; Glio | 2017 |
Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
Topics: Adult; Aged; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Al | 2017 |
Interstitial photodynamic therapy and glioblastoma: Light fractionation in a preclinical model.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Disease Models, Animal; Dose Fractionation, Radiation | 2017 |
Letter: Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Magnetic Resonance Imaging | 2017 |
Histopathological Insights on Imaging Results of Intraoperative Magnetic Resonance Imaging, 5-Aminolevulinic Acid, and Intraoperative Ultrasound in Glioblastoma Surgery.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance | 2017 |
NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy.
Topics: Aminolevulinic Acid; Apoptosis; Autophagy; Brain Neoplasms; Glioblastoma; Humans; Necrosis; NF-kappa | 2011 |
Epithelioid glioblastoma changed to typical glioblastoma: the methylation status of MGMT promoter and 5-ALA fluorescence.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enz | 2011 |
Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence.
Topics: Aminolevulinic Acid; Brain Neoplasms; Fluorescent Dyes; Glioblastoma; Humans; Immunohistochemistry; | 2011 |
Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways.
Topics: Aminolevulinic Acid; Cell Death; Cell Line, Tumor; Glioblastoma; Humans; Hydroxymethylbilane Synthas | 2012 |
Antitumor compound testing in glioblastoma organotypic brain cultures.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Astrocytes; Brain; Brain Neoplasms; Cell Cultur | 2011 |
Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-induced fluorescence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogen | 2011 |
Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro.
Topics: Aminolevulinic Acid; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Movement; Coculture Techniq | 2011 |
Photobleaching-based method to individualize irradiation time during interstitial 5-aminolevulinic acid photodynamic therapy.
Topics: Absorption; Algorithms; Aminolevulinic Acid; Brain Neoplasms; Computer Simulation; Finite Element An | 2011 |
Protoporphyrin IX fluorescence contrast in invasive glioblastomas is linearly correlated with Gd enhanced magnetic resonance image contrast but has higher diagnostic accuracy.
Topics: Aminolevulinic Acid; Animals; Area Under Curve; Cell Line, Tumor; Diffusion; Gadolinium; Glioblastom | 2011 |
5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma.
Topics: Aminolevulinic Acid; Apoptosis; Caspase 8; Cell Line, Tumor; Fas-Associated Death Domain Protein; Gl | 2011 |
A case of late-onset multiple sclerosis mimicking glioblastoma and displaying intraoperative 5-aminolevulinic acid fluorescence.
Topics: Age of Onset; Aminolevulinic Acid; Brain Neoplasms; Diagnosis, Differential; Fluorescent Dyes; Gliob | 2012 |
Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Contrast Media; Female; Fluorescent Dyes; Gliobla | 2012 |
Dynamics of signaling, cytoskeleton and cell cycle regulation proteins in glioblastoma cells after sub-lethal photodynamic treatment: antibody microarray study.
Topics: Aminolevulinic Acid; Apoptosis; Cell Cycle Proteins; Cytoskeleton; Glioblastoma; Humans; Phosphoryla | 2012 |
Is it a glioblastoma? In dubio pro 5-ALA!
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Diagnosis, Differential; Femal | 2012 |
Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin.
Topics: Adult; Aged; Aminolevulinic Acid; Animals; Brain Neoplasms; Cell Transformation, Neoplastic; Female; | 2012 |
Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?
Topics: Adult; Aminolevulinic Acid; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; | 2012 |
Fluorescence-guided resection of gliomas.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Humans; Magnetic Resonance | 2012 |
Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Mapping; Brain Neoplasms; Electroencephal | 2012 |
Prognostic value of ventricular wall fluorescence during 5-aminolevulinic-guided surgery for glioblastoma.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Cerebral Ventricles; Female; Glioblastoma; Humans | 2012 |
Fluorescence-guided brain tumor surgery.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans; Microscopy, Fluorescence; Photosensitizi | 2012 |
Migration of mesenchymal stem cells towards glioblastoma cells depends on hepatocyte-growth factor and is enhanced by aminolaevulinic acid-mediated photodynamic treatment.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Movement; Chemotaxis; Glioblastoma; Hepatocyte Growth Fa | 2013 |
Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids.
Topics: Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Microscopy, F | 2003 |
Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum.
Topics: Adenocarcinoma; Aminolevulinic Acid; Cell Adhesion; Cell Line, Tumor; Cell Membrane; Cell Survival; | 2004 |
Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX.
Topics: Aminolevulinic Acid; Animals; Astrocytes; Cells, Cultured; Fluorescence; Glioblastoma; Humans; Neuro | 2005 |
Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Dose-Response Relationship | 2007 |
5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells.
Topics: Aminolevulinic Acid; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Baculovira | 2007 |
Cell-substrate topology upon ALA-PDT using variable-angle total internal reflection fluorescence microscopy (VA-TIRFM).
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Screening Assays, Antitu | 2007 |
Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report.
Topics: Adult; Aminolevulinic Acid; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans | 2008 |
[Image of the month. 5-aminolevulinic acid (5-ALA) in the guided treatment of malignant brain tumors].
Topics: Aged; Aminolevulinic Acid; Cerebellar Neoplasms; Fluorescent Dyes; Glioblastoma; Humans; Male; Neuro | 2008 |
delta-Aminolevulinic acid effects on neuronal and glial tumor cell lines.
Topics: Aminolevulinic Acid; Cell Survival; Deferoxamine; Glioblastoma; Hemin; Humans; Nervous System Diseas | 1993 |
Protoporphyrin IX fluorescence kinetics in C6 glioblastoma cells after delta-aminolevulinic acid incubation: effect of a protoporphyrinogen oxidase inhibitor.
Topics: Aminolevulinic Acid; Animals; Enzyme Inhibitors; Fluorescence; Glioblastoma; Humans; Kinetics; Oxido | 1999 |
Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Glioblastoma; Humans; Microscopy, Fluorescence; Photochemotherapy; Protoporphyr | 2000 |
Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients.
Topics: Adult; Aged; Aminolevulinic Acid; Brain; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Humans | 2000 |
Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma.
Topics: Aminolevulinic Acid; Brain Neoplasms; Color; Craniotomy; Equipment Design; Female; Glioblastoma; Hum | 2019 |
5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Contrast Media; Female; Follow | 2020 |
Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Fluorescence; Fluorescent Dyes; Gene Express | 2017 |
The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour.
Topics: Adult; Aged; Aldehyde Dehydrogenase 1 Family; Aminolevulinic Acid; Biomarkers, Tumor; Brain Neoplasm | 2017 |
Spectral Radiance of Protoporphyrin IX Fluorescence and Its Histopathological Implications in 5-Aminolevulinic Acid-Guided Surgery for Glioblastoma.
Topics: Aminolevulinic Acid; Biopsy, Needle; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Humans; Im | 2018 |
[Glioblastoma, innovations in surgery].
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Humans; Levulinic Acids; Margins of Excision; Ne | 2017 |